Overview

A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This is a study in otherwise healthy Japanese and non-Japanese participants with elevated low density lipoprotein cholesterol (LDL-C). Following single doses of LY3015014, the safety and tolerability of the drug, how the body handles the drug, and the drug's effect on the body will be evaluated. Participants will remain in the study for approximately up to 6 months.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Antibodies, Monoclonal